Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Fineline Cube Jul 10, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Drug

HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study

Fineline Cube Jul 26, 2023

Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...

Company Deals

Sosei Heptares Acquires Idorsia’s Korea and Japan Units in JPY 65 Billion Deal

Fineline Cube Jul 26, 2023

Japan-based Sosei Group Corporation (TYO: 4565) has announced that its subsidiary, Sosei Heptares, has acquired...

Company Drug

InnoCare Pharma’s ICP-723 Receives NMPA Approval for Pediatric Clinical Study

Fineline Cube Jul 26, 2023

Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases,...

Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease

Fineline Cube Jul 26, 2023

Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported...

Company

Biogen’s Q2 2023 Report Reveals Struggles with Aduhelm and 1,000 Job Cuts

Fineline Cube Jul 26, 2023

US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has released its financial report for the second quarter...

Company Drug

FDA Approves Daiichi Sankyo’s Vanflyta for FLT3-ITD Positive AML Maintenance Treatment

Fineline Cube Jul 25, 2023

The US Food and Drug Administration (FDA) has granted clearance to Japan-based Daiichi Sankyo (TYO:...

Company Drug

Gilead Sciences Halts Development of Magrolimab for HR-MDS Following Phase III Trial Results

Fineline Cube Jul 25, 2023

Gilead Sciences (NASDAQ: GILD) has decided to stop pursuing the potential first-in-class immunotherapy, magrolimab, for...

Policy / Regulatory

EU Commits EUR 3 Million to Strengthen Healthcare Access in Latin America and Caribbean

Fineline Cube Jul 25, 2023

The European Union (EU) has announced a EUR 3 million (USD 3.3 million) funding injection...

Company Drug

AbbVie’s Aquipta and Novartis’s Piqray Receive Regulatory Approvals in Mexico

Fineline Cube Jul 25, 2023

Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted registration approvals to two...

R&D

Oxford and Peking University Study Unveils Genetic Risk Factors in East Asian Population

Fineline Cube Jul 25, 2023

Researchers from the UK’s Oxford Population Health and China’s Peking University have conducted a comprehensive...

Company Deals

Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment

Fineline Cube Jul 25, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam...

Company Deals

Pfizer Ends Partnership with Syros Pharmaceuticals for Sickle Cell Disease Program

Fineline Cube Jul 25, 2023

Syros Pharmaceuticals Inc., (NASDAQ: SYRS) has disclosed in an SEC filing that Pfizer (NYSE: PFE)...

Company Drug

Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial

Fineline Cube Jul 25, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center...

Company Drug

Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment

Fineline Cube Jul 25, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...

Company Policy / Regulatory

Taiwan’s TFDA Orders Recall of Two Nucala Batches Due to Glass Fragments

Fineline Cube Jul 25, 2023

The Food and Drug Administration (FDA) bureau of Taiwan, part of Greater China, has issued...

Company Drug

Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review

Fineline Cube Jul 25, 2023

US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Partnership for Companion Diagnostic Development

Fineline Cube Jul 25, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with...

Company Drug

Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment

Fineline Cube Jul 25, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center...

Medical Device Policy / Regulatory

NMPA Updates List of Medical Devices Exempt from Clinical Evaluation in China

Fineline Cube Jul 25, 2023

The National Medical Products Administration (NMPA) has released an updated version of the “List of...

Policy / Regulatory

Chinese Health Authorities Unveil Key Reform Tasks for Medical System in H2 2023

Fineline Cube Jul 25, 2023

The National Health Commission (NHC), National Development and Reform Commission (NDRC), Ministry of Finance (MoF),...

Posts pagination

1 … 525 526 527 … 693

Recent updates

  • PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates
  • Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia
  • Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
  • Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.